Oaktree Acquisition Corp. III Life Sciences OACC
- Market cap
- $265.0M
- P/E
- —
Follow OACC
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 9.95 | 9.96 | 10.54 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 10.00 | 10.85 | 10.88 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Oaktree Acquisition Corp. III Life Sciences peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DMAA Drugs Made In America Acquisition Corp. | $263.4M | — | Compare |
| DNMX Dynamix Corporation III | $269.7M | — | Compare |
| SOUL Soulpower Acquisition Corporation | $271.6M | — | Compare |
| RAC Rithm Acquisition Corp. | $256.0M | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CEPO Cantor Equity Partners, Inc. | $274.5M | 0.0× | Compare |
| PAII Pyrophyte Acquisition Corp. II | $280.9M | — | Compare |
| AXIN Axiom Intelligence Acquisition Corp 1 | $281.9M | — | Compare |
| CUB Lionheart Holdings | $284.7M | 53.3× | Compare |
Oaktree Acquisition Corp. III Life Sciences (OACC) Latest News
3 Apr
Oaktree Acquisition Corp. III Life Sciences (OACC) has 59% institutional ownership, indicating significant influence over its share price. Six investors hold a majority stake, with Brookfield Corporation as the largest shareholder at 21%. Institutional ownership is generally seen as a positive sign, but it can lead to rapid share price changes if institutions shift their views. Hedge funds own 8.1% of shares, suggesting potential for activist involvement. The general public holds a 27% stake, which can also impact company decisions. Despite the institutional backing, there are warning signs to consider regarding the company's future performance. Institutional ownership indicates credibility but also poses risks if sentiment shifts among major investors.